The purpose of this study is to find out whether combination treatment with the study drugs belantamab mafodotin and nirogacestat is a safe treatment for people who have relapsed or refractory multiple myeloma.
SparkCures ID | 1314 |
---|---|
Trial Phase | Phase 1 |
Enrollment | 9 Patients |
Treatments |
|
Tags |
|
Trial Sponsors |
|
NCT Identifier |
|
The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.
The following criteria is provided for health care professionals.
Inclusion Criteria:
Exclusion Criteria:
Please visit the ClinicalTrials.gov page for historical site information.
View CentersLearn more about how we work with trial sponsors